Literature DB >> 20463060

Post-transcriptional control of human ether-a-go-go-related gene potassium channel protein by alpha-adrenergic receptor stimulation.

Jian Chen1, Kun Chen, Jakub Sroubek, Zhi-Yuan Wu, Dierk Thomas, Jin-Song Bian, Thomas V McDonald.   

Abstract

Stimulation of alpha1-adrenoreceptors (alpha1-AR) acutely alters ion channel behavior via several signaling pathways [calcium and protein kinase C (PKC)]. Little is known about sustained alpha1-adrenergic/PKC signaling and channel regulation as may occur during cardiovascular disease states. Here we describe the effects of prolonged alpha1A-AR and PKC activity on human ether-a-go-go-related gene (HERG) K(+) channels (Kv11.1) expressed in a heterologous expression system. Stimulation of alpha1A-AR with phenylephrine or direct activation of PKC with phorbol ester increased HERG channel protein abundance and K(+) current density in a time- and dose-dependent manner. Channel augmentation reached a steady-state plateau within 24 h with a 2- to 6-fold induction. Phorbol ester and moderate alpha1A-AR stimulation enhanced HERG abundance in a PKC-dependent fashion but with stronger alpha1A-adrenergic stimulation; protein kinase A (PKA)-dependent activity also contributed. Comparable channel induction of other cardiac K(+) channels was not seen in this system. Comparison of wild-type HERG and channels with either mutated PKC phosphorylation sites (HERGDeltaPKC) or mutated PKA phosphorylation sites (HERGDeltaPKA) suggested that the mechanisms of augmentation of HERG by the two kinases were partially overlapping. The PKC-dependent effect was largely due to enhanced synthetic rates. Stimulation of alpha1-AR in cultured rat neonatal cardiac myocytes also enhanced the abundance of ERG channels. These findings show that alpha1A-AR stimulation is capable of influencing the balance of HERG channel synthesis and degradation via multiple signaling pathways, a process that may have relevance in cardiac diseases and treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463060      PMCID: PMC2917855          DOI: 10.1124/mol.109.062216

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.

Authors:  U Schubert; L C Antón; J Gibbs; C C Norbury; J W Yewdell; J R Bennink
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

Review 2.  Electrophysiological remodeling in hypertrophy and heart failure.

Authors:  G F Tomaselli; E Marbán
Journal:  Cardiovasc Res       Date:  1999-05       Impact factor: 10.787

Review 3.  Seven-transmembrane-spanning receptors and heart function.

Authors:  Howard A Rockman; Walter J Koch; Robert J Lefkowitz
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

4.  14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity.

Authors:  Anna Kagan; Yonathan F Melman; Andrew Krumerman; Thomas V McDonald
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

5.  Cyclic AMP regulates the HERG K(+) channel by dual pathways.

Authors:  J Cui; Y Melman; E Palma; G I Fishman; T V McDonald
Journal:  Curr Biol       Date:  2000-06-01       Impact factor: 10.834

6.  Analysis of the cyclic nucleotide binding domain of the HERG potassium channel and interactions with KCNE2.

Authors:  J Cui; A Kagan; D Qin; J Mathew; Y F Melman; T V McDonald
Journal:  J Biol Chem       Date:  2001-02-26       Impact factor: 5.157

Review 7.  Cardiac alpha 1-adrenergic drive in pathological remodelling.

Authors:  Elizabeth A Woodcock; Xiao-Jun Du; Melissa E Reichelt; Robert M Graham
Journal:  Cardiovasc Res       Date:  2007-11-21       Impact factor: 10.787

8.  Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome.

Authors:  E Ficker; A T Dennis; C A Obejero-Paz; P Castaldo; M Taglialatela; A M Brown
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

9.  The dominant negative LQT2 mutation A561V reduces wild-type HERG expression.

Authors:  A Kagan; Z Yu; G I Fishman; T V McDonald
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

10.  Small GTPase determinants for the Golgi processing and plasmalemmal expression of human ether-a-go-go related (hERG) K+ channels.

Authors:  Brian P Delisle; Heather A S Underkofler; Brooke M Moungey; Jessica K Slind; Jennifer A Kilby; Jabe M Best; Jason D Foell; Ravi C Balijepalli; Timothy J Kamp; Craig T January
Journal:  J Biol Chem       Date:  2008-11-24       Impact factor: 5.157

View more
  5 in total

1.  PKC-dependent activation of human K(2P) 18.1 K(+) channels.

Authors:  Ann-Kathrin Rahm; Jakob Gierten; Jana Kisselbach; Ingo Staudacher; Kathrin Staudacher; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Mechanisms underlying the protein-kinase mediated regulation of the HERG potassium channel synthesis.

Authors:  Yamini Krishnan; Yan Li; Renjian Zheng; Vikram Kanda; Thomas V McDonald
Journal:  Biochim Biophys Acta       Date:  2012-05-18

3.  Different protein kinase C isoenzymes mediate inhibition of cardiac rapidly activating delayed rectifier K+ current by different G-protein coupled receptors.

Authors:  Xueli Liu; Yuhong Wang; Hua Zhang; Li Shen; Yanfang Xu
Journal:  Br J Pharmacol       Date:  2017-11-07       Impact factor: 8.739

4.  Protein kinase A activity at the endoplasmic reticulum surface is responsible for augmentation of human ether-a-go-go-related gene product (HERG).

Authors:  Jakub Sroubek; Thomas V McDonald
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

5.  A dual mechanism for I(Ks) current reduction by the pathogenic mutation KCNQ1-S277L.

Authors:  Jerri Chen; Michael Weber; Sung Yon Um; Christine A Walsh; Yingying Tang; Thomas V McDonald
Journal:  Pacing Clin Electrophysiol       Date:  2011-09-02       Impact factor: 1.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.